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Abstract
Structural diversity in the peptide binding sites of the redundant classical MHC antigen presenting molecules is strongly
selected in humans and mice. Although the encoded antigen presenting molecules overlap in antigen presenting function,
differences in polymorphism at the MHC I A, B and C loci in humans and higher primates indicate these loci are not
functionally equivalent. The structural basis of these differences is not known. We hypothesize that classical class I loci differ
in their ability to direct effective immunity against intracellular pathogens. Using a picornavirus infection model and
chimeric H-2 transgenes, we examined locus specific functional determinants distinguishing the ability of class I sister genes
to direct effective anti viral immunity. Whereas, parental FVB and transgenic FVB mice expressing the H-2K
b gene are highly
susceptible to persisting Theiler’s virus infection within the CNS and subsequent demyelination, mice expressing the D
b
transgene clear the virus and are protected from demyelination. Remarkably, animals expressing a chimeric transgene,
comprised primarily of K
b but encoding the peptide binding domain of D
b, develop a robust anti viral CTL response yet fail
to clear virus and develop significant demyelination. Differences in expression of the chimeric K
ba1a2D
b gene (low) and D
b
(high) in the CNS of infected mice mirror expression levels of their endogenous H-2
q counterparts in FVB mice. These
findings demonstrate that locus specific elements other than those specifying peptide binding and T cell receptor
interaction can determine ability to clear virus infection. This finding provides a basis for understanding locus-specific
differences in MHC polymorphism, characterized best in human populations.
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Introduction
MHC class I antigen presenting molecules sample peptides
generated intracellularly and present them on the surface of cells
to CD8+ T cells bearing class I restricted T cell receptors [1–3].
The MHC class I multigene families in mice and humans contain
three genes encoding classical antigen presenting molecules [4],
generally considered to have redundant functions. These classical
MHC I molecules direct immune responses, determine host
resistance to disease, and are considered key variables in vaccine
design. However, certain lines of evidence indicate that the
classical HLA (A, B, and C) and H-2 (K, D, and L) genes may not
strictly be redundant, but instead have distinctive functions.
Delineating these differences would be important for understand-
ing the roles of class I genes in disease and shape rational
development of vaccines to prevent or treat viral infections and for
the immunotherapy of cancers.
Immunogenetic data provide the primary support for the
hypothesis that MHC class I classical genes do not function
equivalently. MHC polymorphism is understood in the context of
naturally selected variation in the ability of the immune system to
deal with constantly changing challenges by pathogens. Allelic
comparisons at the nucleotide level provide convincing evidence
that natural selection for amino acid diversity in residues
positioned to interact directly with bound peptide favors amino
acid replacements over synonymous substitutions [5,6]. The
nature of MHC polymorphism in mammal population is best
understood from meta analysis of world wide studies of human
populations. The numbers of identified alleles in human and
chimpanzee populations assigned to the A, B, and C loci [5–8]
differ substantially (e.g. the 1641 HLA B alleles .1176 A alleles
.808 C alleles as enumerated in the IMGT/HLA Database,
European Bioinformatics Institute). The probability that any of
these three loci has an equivalent number of alleles is less than
10
215. This difference in the numbers of alleles is a strong
indication that the classical class I loci are not functioning
equivalently. MHC polymorphism in South American Indian
populations [9–14] provides a snapshot of the selective forces
operating over the 15,000 years following the settling of the new
world by their Asian ancestors [15]. In these Amerindian
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superfamilies from the old world have been identified, 21
subfamily members have emerged (discounting identified old-
world superfamily allelic prototypes such as B15:01 and B35:01).
In contrast, 8 subfamily alleles at the A locus are present,
representing 4 of the 21 old world allelic families, and just 1 new
variant at the C locus. Again, this pattern strongly diverges from
the null hypothesis that the numbers of HLA A, B, and C alleles are
evolving at the same rate in South America (P=0.0121 for
comparison of A and B, and 0.0195 for comparison of A and C). A
similar pattern of natural selection appears to be functioning in
chimpanzee populations where the numbers and structural
diversity among Patr B alleles is larger than found at the Patr A
and C loci [7,8]. The different selection pressures operating on the
A, B, and C loci, noted as well by others [5,16], provides a
compelling argument that each of these immune response
regulatory genes do not function equivalently.
Interpretations of the unequal numbers of alleles that have
emerged at the class I loci in humans and chimpanzees have
focused on their peptide binding properties, as it is well known that
amino acid changes that affect peptide binding by MHC I
molecules influence immune function. This argument focuses on
functional differences distinguishing alleles of a single locus.
Because there are more than 800 to 1,600 allelic variants at the
three human loci with widely disparate abilities to bind and
present peptides, explanations predicated on allele specific peptide
binding properties seem unsatisfactory. Here, we propose a
different explanation: locus specific differences in gene expression determine
the relative importance of the class I genes for survival, driving locus specific
frequencies of emerging allelic variants for the classical MHC genes. The
implication is that the classical class I genes are not equally
effective in directing immunity against certain pathogens, and
therefore, may not be equally effective in targeting vaccine
antigens against viruses and perhaps cancers. We propose that the
C locus alleles will be less effective antigen presenting molecules
than the A locus alleles, which in turn will be less effective than the
B locus alleles. This hierarchy is noteworthy as most vaccines are
designed by convenience to target the A locus antigen presenting
molecules because of their more limited polymorphisms.
Because the antigen presenting function of MHC I molecules
are determined by their highly polymorphic peptide binding
domains, variation within allelic series will overshadow differences
among the proteins derived from different loci. In the laboratory
mouse, the structures of genes expressed in vivo can be readily
manipulated, and we have used this property to illustrate the
principle underlying our hypothesis.
In the mouse where large numbers of H-2 K and D classical class
I alleles have been described, the genetic ability to control
picornavirus-induced demyelinating disease in the spinal cord
maps to the D locus class I gene cluster (H-2 D and L) and does not
seem to be influenced by the myriad of alleles present at the K
locus [14]. This suggests that ability to resist persistent infection by
Theiler’s murine encephalomyelitis virus (TMEV) might be an
example of classical class I loci differing in ability to provide
effective immunity against a viral pathogen. An extensive analysis
of MHC mediated resistance to TMEV demonstrated that certain
alleles of the D gene can direct virus-specific CD8+ T cell
immunity that is responsible for clearing virus infection from the
CNS [9,10,12–14]. Whereas only certain D region alleles provide
protection against persisting virus infection, alleles of the sister
locus H-2K never seem to matter. Our studies of gene conversion
mediated interchange of coding sequences among the a1 and a2
coding sequences of MHC genes in the mouse indicate that
natural history of these sister genes has resulted in a complete
scrambling of sequence diversity [11,17–19]. This implies that
structural diversity in the peptide and T cell receptor interaction
domains of the D and K molecules is not likely the source of their
differential ability to direct an effective and protective immune
response against TMEV infection. In humans where interlocus
exchange is more limited [8], this situation is approximated by the
large numbers of allelic variants at the HLA A, B and C loci
encoding distinctive peptide binding sites.
There are two competing hypotheses explaining the immune
response phenotypes of mouse strains susceptible and resistant to
persisting TMEV infection. The first is that certain MHC I alleles
arecapableofeffectivelypresentingviralpeptidestotheCD8+ Tce ll
compartment, and these effective alleles happen by chance to belong
to the series of class I genes encoded within H-2D. The second
possibilityisthatH-2DandH-2Kgenesarefunctionallydistinct,such
that while some alleles of H-2D can direct effective virus immunity,
alleles of H-2K are ineffective as a group, irrespective of their ability
to bind viral peptides and present them to CD8+ Tc e l l s .
Here we show that structural attributes of K and D genes other
than their coding sequences specifying peptide binding properties
are responsible for their differential ability to direct protective
immunity against a picornavirus infection. These differences
influence the relative expression of H-2K and D. This finding
provides structural evidence differentiating the functional proper-
ties of the classical class I loci and relates these differences to the
ability to fight a virus infection. This framework provides a basis
for understanding the diverging evolutionary histories of members
of the ‘‘classical’’ MHC class I gene family in animal populations,
and provides context to our understanding of the polymorphism
differences evident at the human HLA A, B, and C loci.
Results
Viral clearance is determined by regions outside of the
peptide binding domain of the H-2D
b gene
In order to study the structural properties of the H-2D and H-
2K class I genes that are responsible for directing effective viral
Author Summary
MHC I genes are best understood as regulators of antiviral
immunity. In humans and mice there are 2 to 3
homologous MHC I genes encoding highly polymorphic
antigen presenting molecules which present virus proteins
to T lymphocytes. A world wide effort has catalogued
more than 6,300 classical HLA MHC I alleles in human
populations, making these MHC loci among the best
characterized polymorphic gene families. However, there
has been little progress in understanding implications of
the differences in polymorphism present at the HLA A, B,
and C loci. By expressing MHC I molecules capable of
presenting viral antigens under regulatory determinants
from different sister MHC I genes of the mouse, we address
the hypothesis that locus-specific differences in the
regulation of the homologous MHC I sister genes can
determine whether alleles at any particular locus can
effectively target protective immunity against virus infec-
tion. We find that while the ability to activate cellular
immune effectors is determined by the highly polymorphic
MHC I sequences encoding the peptide binding domain,
the ability of these T lymphocytes to effectively clear virus
from the central nervous system can also be determined
by gene sequences mapping outside of this region.
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encoding the K
b or D
b (Figure 1A) genes into susceptible FVB mice.
To control for possible gene integration positional effects, multiple
independent founder lines were analyzed. One founder line of the
K
b transgene and three founder lines of the D
b transgene were
evaluated for susceptibility to TMEV induced demyelination.
TMEV infected K
b transgenic animals developed focal areas of
demyelination similar to non-transgenic animals (Figure 2A and
B). Few of the D
b transgenic mice demyelinated (Table 1),
demonstrating resistance compared to the littermate controls
(Figure 2C and D) which suggests that transfer of the genomic
fragments faithfully reproduced the disease susceptibility pheno-
types of interest.
To evaluate whether factors other than peptide binding by
MHC class I molecules determine disease susceptibility, we sought
to remove the peptide binding and TCR interaction encoding
domain as a variable in our analysis. Because the inability to
present peptides to T cells would mask the hypothesized properties
of interest, we chose to substitute the D
b encoded antigen
presenting domain a1a2 for its homologous counterpart in the
K
b gene. This region is known to determine the peptide binding
properties of MHC I antigen presenting molecules, as well as, the
specificity of MHC ligand interactions with T cell receptors [3,20].
The resulting chimeric genomic transgene (K
ba1a2D
b) contained
the coding sequences of the a1a2 peptide binding domain and
non-coding intronic sequences from the 39 end of intron 1, all of
intron 2, and the 59 region of intron 3 from D
b (Figure 1A and B).
The remaining regulatory, untranslated regions and structural
features of this transgene were derived from a K
b genomic clone
[21]. Equivalent expression of the D
b and the K
ba1a2D
b transgenes
was observed in transiently transfected 293T cells (Figure 1C).
Eight independent FVB founder lines expressing the K
ba1a2D
b
transgene were established and analyzed for their susceptibility to
TMEV induced demyelinating disease. Mice from 8 K
ba1a2D
b
founder lines developed demyelinating lesions (Table 1), similar to
transgene negative matched littermate controls (Figure 2E and F).
We conclude from this analysis that the K
ba1a2D
b chimeric
transgene lacks necessary determinants to provide resistance to
TMEV induced demyelinating disease.
Since the level of demyelination correlates with levels of
persisting virus in the CNS, we infected D
b and K
ba1a2D
b
transgenic mice with TMEV for 21 to 24 days to evaluate whether
transgenes conferred protection from chronic virus infection. We
analyzed TMEV specific transcripts from chronically infected
brain and spinal cord and found that the virus persisted in both
tested sublines of K
ba1a2D
b mice at levels similar to levels seen in
the non-transgenic FVB hosts (Figure 2G and H). In contrast,
levels of virus were detected at low levels in the two evaluated D
b
transgenic founders, one of the original 3 D
b founder lines, and a
fourth D
b founder line expressing a D
b transgene with introduced
LoxP sites. The critical role of D
b in viral clearance is illustrated by
the deletion of D
b in a version of the transgene containing LoxP
Figure 1. Generation of FVB K
ba1a2D
b transgenic mice. (A) Segments of H-2K
b EcoRI and H-2D
b HindIII were used to generate a chimeric
genomic construct with an H-2D
b Sal I/XbaI fragment on an H-2K
b backbone. (B) Expression of the construct yields a chimeric MHC class I molecule
composed of the a1a2 domain from H-2D
b and the a3 domain from H-2K
b. (C) Verification of H-2D
b and K
ba1a2D
b transgene expression in 293T cells
by flow cytometry. Data are mean fluorescence intensity of phycoerythrin labeled cells.
doi:10.1371/journal.ppat.1002541.g001
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introduction of Cre recombinase into the mice under control of
the E2a promoter. Significantly higher levels of viral transcript
were observed in FVB D
b-LoxP Cre mice than in the FVB D
b- LoxP
subline (Figure 2G).
Acute and chronic CTL responses to immunodominant
VP2121–130 are generated equivalently in H-2K
b a1a2D
b
and H-2D
b transgenic mice
As shown previously [12], the clearance of TMEV is dependent
on the generation of H-2D
b restricted CD8 T-cell responses to the
immunodominant peptide VP2121–130 (CD8
VP2+). This implies
that the T-cell repertoire is available to respond to this antigen and
that the antigen specific CTL are able to efficiently target virus
infected cells disrupting the infection. Since K
ba1a2D
b transgenic
mice fail to clear virus from the CNS, we analyzed brain
infiltrating lymphocytes from 6 day TMEV infected D
b and
K
ba1a2D
b transgenic mice for the presence of CD8+ VP2121–130-
specific T cells. As expected, the non-transgenic FVB (H-2
q)
infiltrates were negative for D
b-restricted VP2121–130-specific CD8
T cells (Figure 3A); in contrast, the D
b transgenic mice developed a
robust CD8+ VP2121–130-specific response. Surprisingly, the
susceptible K
ba1a2D
b transgenic hosts developed a CD8+
response, equivalent to the response seen in the resistant D
b
transgenic hosts, demonstrating that the VP2121–130 responsive
CD8 T-cells were available, activated, and recruited to the brain
equivalently by both resistant and the susceptible transgenic
animals.
We wondered whether the presence of CD8+ T-cells specific for
VP2 in the CNS suggested a defect in the ability of the T cells to
Figure 2. Spinal cord demyelination and persistent virus
infection in FVB K
ba1a2D
b transgenic mice. (A) Transgenic
expression of H-2K
b fails to protect from TMEV induced demyelination,
similar to non-transgenic control (B). (C) Expression of H-2D
b transgene
protects FVB mice from TMEV induced demyelination present in
littermate controls (D). (E) Expression of a chimeric K
ba1a2D
b molecule
fails to protect from demyelination, similar to non-transgenic (F). (G)
Relative TMEV RNA levels in spinal cords from transgenic mice infected
for 21 days (* p,0.05 by ANOVA). (H) Relative TMEV RNA levels in the
brains of transgenic mice after 24 days of infection.
doi:10.1371/journal.ppat.1002541.g002
Table 1. Spinal cord pathology.
Transgene/Founder Demyelination
Pos Neg Total %
Normal Littermates 41 6 47 87
H-2K
b 10 0 11 100
a
NLM/H-2K
b 51 6 67 88
H-2D
b
Founder 1 1 2 3
Founder 2 1 2 3
Founder 3 3 9 12
Total 5 13 18 28
H-2K
b/D
ba1a2
Founder 1 6 1 7
Founder 2 8 1 9
Founder 3 8 3 11
Founder 4 4 2 6
Founder 5 3 2 5
Founder 6 4 2 6
Founder 7 4 2 6
Founder 8 2 4 6
Total 39 17 56 70
bc
Overall Chi Square analysis (P,0.001).
aFisher Exact Test NLM VS H-2K
b (P=0.577).
bFisher Exact Test H-2D
b vs K
b/D
ba1a2 (P=0.0198).
cFisher Exact Test NLM/H-2K
b vs K
b/D
ba1a2 (P=0.0105).
30% TMEV resistance attributed to peptide presentation.
70% TMEV resistance attributed to differences between K and D loci.
doi:10.1371/journal.ppat.1002541.t001
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for their ability to kill VP2121–130 pulsed target cells. T cells from
animals capable and incapable of eliminating persisting virus killed
the peptide pulsed targets in vitro (Figure 3B). This indicates that
the population of T cells required for viral clearance is present
within the repertoire of K
ba1a2D
b transgenic mice. They are
activated by virus infection, capable of killing cells presenting viral
antigens, and are recruited to the infected CNS. Therefore, it
appears that targeting the infected cells in vivo is deficient in
K
ba1a2D
b transgenic hosts.
Elements outside of the a1a2 coding region determine
the expression levels of the MHC class I transgenes
We next examined the expression of the MHC class I transgenes
for evidence of differential expression. Populations of skin
fibroblasts were established from animals of each parental and
transgenic FVB mice. The FVB K
ba1a2D
b fibroblasts had
significantly reduced accumulations in RNA from their class I
transgene in comparison to the FVB D
b fibroblasts, before and
after treatment with IFNc (Figure 4A). Direct comparison was
possible because the assessed transcripts shared identical sequences
that were probed using quantitative PCR. In contrast, fibroblasts
from FVB, FVB-D
b, and FVB-K
ba1a2D
b mice were found to
have equivalent amounts of RNA from the endogenous D
q locus,
before and after IFNc treatment. The response of the transgenes
to IFNc appears to be equivalent to the response of the
endogenous D locus based on fold-increase induced by the
cytokine. The fold increase of the D
q (8.260.9) and D
b (11.262.0)
genes in the FVB D
b fibroblast were not statistically different,
similar to that observed in the FVB K
ba1a2D
b fibroblasts (D
q,
6.160.5 and D
b, 6.160.8). We considered the possibility that the
observed differences reflect variation in mRNA stability, but found
no differences in mRNA stability between H-2D
b transcripts from
the two transgenes (Figure 4A). We compared this to the less stable
transcript derived from tumor necrosis factor alpha (TNFa) [22]
which demonstrated a 3 to 5 fold reduction in transcript level after
6 hours of treatment with actinomycin D. We conclude that the
primary functional difference observed can be attributed to the
base-line expression levels of the D
b and K
ba1a2D
b transgenes
and not to their ability to respond to IFNc.
A similar difference in expression level was observed in the
brains of TMEV infected mice (Figure 4B). Again, brain tissue
from FVB K
ba1a2D
b transgenic mice expressed equivalent levels
of endogenous D
q but had reduced levels of K
ba1a2D
b expression
compared to FVB D
b after TMEV infection. Expression of the
endogenous K locus in brain cells from wild-type FVB mice
infected with TMEV was also reduced relative to the D-region
class I genes, most pronounced for the L locus (Figure 4C). In
contrast, the levels of K, D, and L expression were more
comparable in the spleen of infected mice. The differential pattern
of expression was seen in the spinal cord of TMEV infected
transgenic and wild type animals (Figure 4D). D
b expression was
higher in two independent transgenic lines as compared to two
independent K
ba1a2D
b transgenic lines. Comparison of endog-
enous gene expression 21 days after virus infection is complicated
by viral clearance in the animals expressing the D
b transgene
relative to the other FVB mouse lines analyzed (Figure 2G).
Clearance of the virus is associated with down regulation of D
q,
L
q, and K
q transcripts in the D
b mice relative to the expression
levels seen in FVB, K
ba1a2D
b, and D
bLoxP-cre mice. This
expression pattern relative to virus levels is opposite to the pattern
for D
b and K
ba1a2D
b transgenes (top left panel, Figure 4D),
suggesting that the functional difference in expression of the
transgenes may be greater than measured in the mice 21 days after
infection when virus levels are dropping in the D
b transgenic mice.
Also noted in these experiments was the lower level of H-2K
q
transcripts relative to D
q and L
q detected in all the mice analyzed,
a finding consistent with our cDNA analysis in Figure 4C.
Next, we assessed the expression of the transgene and
endogenously encoded class I genes at the protein level. The
mean fluorescence intensity of class I molecules expressing the
B22.249 (D
b) defined epitope shared by D
b and K
ba1a2D
b was
comparable in peripheral blood mononuclear cells for all the
tested mouse lines, although a slight, but statistically significant
lower expression was seen for the chimeric transgene encoded
molecules (Figure 5A). A similar expression pattern was seen using
spleen cells when comparing independent founder lines
(Figure 5B). Expression of the K
ba1a2D
b transgene was confirmed
in these mice by using an antibody [23] with a reactivity pattern
dependent, in part, on the a3 region of K
b (Figure 5C).
The central element of our hypothesis is that the expression of
class I loci in tissues within the body are not equivalent and that
cells, which do not adequately express class I antigen presenting
molecules, can provide safe harbor for infecting virus despite the
presence of infiltrating, activated, anti-viral T cells. In the specific
case of CNS infection by TMEV, we hypothesize that the K locus
Figure 3. FVB K
ba1a2D
b transgenic mice generate functional
CTL responses against the immunodominant VP2121–130 pep-
tide. (A) Control H-2D
b/E749–57 and TMEV specific H-2D
b/VP2121–130
tetramer and CD8 staining of acute CD45+ lymphocytes isolated from
the brains of transgenic and non-transgenic mice infected with TMEV
for 6 days (* p,0.05 by ANOVA). (B) VP2121–130 specific killing of peptide
pulsed targets by acute brain infiltrating lymphocytes isolated from H-
2D
b and H-2K
ba1a2D
b transgenic mice compared to killing of non-
pulsed EL-4 cells.
doi:10.1371/journal.ppat.1002541.g003
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D locus is. Therefore, we next sought to identify cells which under
express K
ba1a2D
b relative to D
b during virus infection. One
limitation with this approach is that there are many different cell
types in the CNS, and our hypothesis only specifies that some cells
need to under express H-2K. Therefore, this hypothesis will be
difficult to assess systematically. Nevertheless, using a candidate
approach, we examined class I expression by microglial cells, a
brain resident cell population that can be recovered from normal
and infected brain for analysis by flow cytometry [24]. Microglial
cells can be discriminated from infiltrating leukocytes and other
resident brain cells by their intermediate expression of the
leukocyte marker CD45. We enriched CD45 positive cells from
brain homogenates using percol gradients and analyzed the CD45
intermediate cells for expression of D
b and K
ba1a2D
b before
(Figure 5D) and after (Figure 5E) TMEV infection. H-2D
b is
expressed at a significantly higher level on microglial cells than is
K
ba1a2D
b. Following infection with TMEV, expression of D
b is
uniformally increased, while the increase of expression of
K
ba1a2D
b is more variable. Importantly, a portion of the
microglial cells isolated from TMEV infected K
ba1a2D
b trans-
genic mice do not express levels of the encoded H-2 antigen
presenting molecules beyond the median level of the negative
control (shaded in Figure 5E). This expression pattern is consistent
with our hypothesis that determinants mapping outside the
peptide binding domains of the K and D class I genes differentially
regulate tissue specific expression and that a population of cells in
the CNS may not adequately express the relevant MHC encoded
antigen presenting molecule needed to clear virus.
Discussion
In this report we show, in agreement with previous reports
[25,26], that the ability of the H-2D
b gene to incite a virus specific
CTL response maps to the coding sequences of the peptide
binding domain of the class I glycoprotein. However, we also
found that induction of a virus specific CTL response that is
recruited into the infected CNS is not sufficient to clear virus
infection and protect the mice from virus induced demyelination
[27]. Another, yet to be defined, attribute of the D
b gene is
necessary for effective immunity to persistent virus infection. This
attribute of D
b is not shared by the K
b gene and maps outside of the
peptide binding domain coding sequences and adjacent intron
sequences. We demonstrated in earlier studies using bone marrow
chimeras that activated brain infiltrating CTL must be able to
recognize virus on infected cells in order to clear the virus infection
[27]. One possibility is that the H-2K antigen presenting
molecules are not expressed sufficiently on populations of TMEV
infected cells in the CNS, preventing the effective clearance of the
virus by K restricted CTL.
The necessary structural sequences for directing effective
antiviral immunity are present within the 8 kb genomic DNA
fragment introduced as a transgene in our study, as four founder
lines prepared from susceptible FVB mice acquired a resistant
phenotype using demyelination (Table 1) or viral clearance
(Figure 2) as criteria. In contrast, the eight founder lines prepared
using the K
ba1a2D
b transgene displayed a susceptible phenotype.
Therefore, a systematic analysis of recombinant transgenes should
allow identification of the critical sequences determining the
functional differences between these two classical class I genes.
Brahic and colleagues reported that a transgene encoding a
similar chimeric glycoprotein comprised of the a1a2 domain of D
b
in the context of the a3, transmembrane, and cytoplasmic regions
of K
b was able to clear TMEV infection from the CNS [28]. The
chimeric gene used in that study contained a larger segment of D
b
non-coding sequences than did the chimeric transgene used in our
study. One possibility is that regulatory sequences determining the
ability of the D class I gene to direct effective sterilizing immunity
against the virus are located within the additional D
b sequences in
the Brahic construct. Another possibility is that a fortuitous
integration event bestowed a wider expression phenotype on the
transgenic mouse used in that study. Our finding that 8 different
K
ba1a2D
b founder lines expressed similar demyelinating pheno-
types known to be related to inability to clear chronic virus
infection provides confidence in our conclusion that structural
components of the transgenes, and not fortuitous integration
events, determined the different phenotypes of the transgenic
animals we studied. The ability of our chimeric transgene to
promote the activation and recruitment of virus specific CTL to
the infected CNS in a manner equivalent to the phenotype
bestowed by the parental D
b transgene has led us to a different
conclusion from the Brahic group. We conclude that the ability of
peptide binding domain to present critical viral peptide antigens
and elicit cellular immunity is not sufficient to direct effective
antiviral immunity to the TMEV picornavirus and that properties
distinguishing D region class I genes from the K locus genes
determine this difference.
We had previously noted using immunohistology that the K and
D region proteins of the H-2
q haplotype are differentially
expressed in TMEV infected brain tissues during acute and
chronic infection [29]. In those studies, we found early up
regulation of H-2K and H-2D protein in the brain. While H-2D
expression was maintained during the chronic phase of infection,
expression of H-2K diminished. Here, we have extended our
analysis of the expression of H-2
q haplotype genes during TMEV
infection at the RNA level. We find that H-2L
q is the most
prominently expressed class I gene in TMEV infected mice, with
minimal expression of H-2K
q. Our comparison of the chimeric and
D
b transgenes showed that D
b is expressed at substantially higher
levels than the chimeric gene in TMEV infected CNS of
transgenic mice, a pattern that mimics the endogenous K
q and
L
q genes. H-2L
q and H-2D
b are close evolutionary relatives as
indicated by dendogram analyses based on their gene sequences
[19]. Their notation as L and D locus alleles is an accident of
mouse nomenclature. We have argued that all the classical D
region genes can move into the D and L locus positions on the
chromosome by unequal recombination [30], and therefore, can
be considered part of the same allelic series, although structural
regulatory differences derived from two ancient loci now mixing
by the polymorphic gene organization may be retained in mouse
Figure 4. Non-equivalent mRNA expression of MHC class I genes due to elements outside of the a1a2 coding region of the
transgenic D locus. (A) FVB skin fibroblast mRNA levels for H-2D
b and H-2D
q with or without treatment with IFNc (**p,0.01 comparing D
b versus
K
ba1a2D
b without or with IFNc). (Third panel) Transgenic mRNA stability as determined by degradation of mRNA transcripts after actinomycin D
inhibition of transcription. qRT-PCR amplification was used to detect H-2D
b and TNFa specific transcripts from FVB D
b and FVB K
ba1a2D
b transgenic
fibroblasts previously treated with IFNc. (B) H-2D
q mRNA expression in TMEV infected brain tissue from H-2D
b and FVB K
b a1a2D
b transgenic mice
(** p,0.05). (C) Competitive RT-PCR and sequence identity for MHC specific transcripts from the brain and spleen of TMEV infected mice (* p=0.091,
Fisher Exact Test comparing the ratio of K
q and L
q sequences recovered). (D) mRNA expression of transgenic and endogenous H-2 genes (** p,0.01
by Two-way ANOVA).
doi:10.1371/journal.ppat.1002541.g004
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b is protective because
it is highly expressed in infected tissues and presents viral peptides
efficiently, while L
q, also highly expressed, does not effectively
present viral peptides. H-2D
q expression, while measurable, does
not appear to be at the level of H-2L
q. How other D region genes
in the mouse are expressed, including those of the resistant H-2
d
and H-2
k haplotypes, remains to be determined.
An important insight emanating from our studies is that the
classical MHC I genes do not appear to function equivalently
throughout the body. While these molecules are all capable of
binding endogenously generated peptides and presenting both
foreign and self antigens to CD8+ T cells, at least some of the K
locus alleles (K
q and K
b) are expressed at lower levels than their D
region counterparts (L
q, D
b, and even D
q) by fibroblasts and some
cells in the CNS. All these MHC I genes appear to be expressed
more similarly in some tissues outside of the CNS, most notably
spleen cells and by brain infiltrating leukocytes during infection.
The implication is that regulation of MHC I gene expression in
the CNS and in spleen cells differs in ways that requires more than
the up regulation of a single gene regulatory factor not normally
expressed in CNS tissues. Our model provides a way to identify
the elements governing the regulatory mechanisms active in the
CNS.
Although we do not know the precise mechanism responsible
for differential regulation of K and D genes in the mouse, both of
our transgenes are responsive to IFNc, but differ in basal
expression in various tissues. This expression pattern is consistent
with previous findings demonstrating that distinct transcriptional
pathways regulate basal and activated MHC class I expression
[31] and locus specific differences in the structure of MHC class I
promoters [25,26] reflected in patterns of transcription factor
binding [32,33]. The precise details of the mechanisms that
determine differential expression of class I genes in different
species may not be the same.
Finally, our finding that MHC I loci have different inherent
abilities to direct effective class I mediated cellular immunity to
viruses provides a model for understanding the strong selection
differences implicit in the structures of polymorphism of class I
genes in human and chimpanzee populations. Whereas the B locus
alleles are vibrantly selected for diversity in the coding blocks for
their peptide binding sites, A and C locus alleles are less so. The B
locus in humans and the D loci in mice occupy orthologous
positions within their respective MHC [34] raising the possibility
that these genes may share canonical regulatory motifs and
expression patterns. Whether locus differences in polymorphism
can be traced to differential regulation of the primate A, B, and C
loci in the CNS or elsewhere in the body remains to be
determined. Nonetheless, the implication is that the A, B, and C
loci are not functioning equivalently throughout the body. This
raises provocative questions about the wisdom of selecting the less
polymorphic HLA-A locus antigen presenting proteins as targets
for vaccine development. The requirements for initiating an
immune response and for resolving infection are different. The
absence of expression of A locus proteins in key tissues (e.g. sites of
infections) could promote conditions of chronic inflammation
without effective resolution of immunity at targeted tissues. We
propose that differences in gene regulation may be the underlying
reason why A and C diversity is lagging behind B diversity in
human populations.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocols were approved by the Institutional Animal Care and Use
Committee of Mayo Clinic (#A25704 and #A12304). All mice
were anesthetized with isoflurane prior to intracranial virus
infection.
Mice
C57BL/6 mice were obtained from Jackson Laboratories (Bar
Harbor, ME, USA). B10, 129 and FVB mice were obtained from
the Mayo Clinic Transgenic Core Facility.
Virus infection
Virus infection was introduced into the CNS via intracerebral
inoculation with 2610
5 PFU of the Daniel’s strain of Theiler’s
murine encephalomyelitis virus (TMEV). Acute infection with
TMEV was analyzed at day 6 and all chronically infected animals
at greater than 45 days. All animals were housed and cared for
according to institutional and NIH guidelines for animal care and
use.
Transgenic mice
The generation of FVB K
b and FVB D
b transgenic mice was
described previously [12]. FVB K
ba1a2D
b transgenic mice were
generated by the Mayo Transgenic Core facility. To generate the
chimeric construct a Sal I site was introduced into a Hind III-
EcoRI fragment of H-2K
b at genomic position 136. A Sal I/XbaI
PCR fragment was generated from a cloned H-2D
b vector [35]
and engineered into the H-2K
b backbone vector.
Function was verified in 293T cells by transfection and FACS.
Briefly, 293T cells were plated in 6 well plates one day prior to
transient transfection with GFP and the H-2K
b, H-2D
b and H-
2K
ba1a2D
b constructs using Fugene 6 transfection reagent
(Roche Diagnostics Corporation, Indianapolis, IN). Twenty-four
hours later cells were trypsinized and stained with excess H-2D
b
specific antibody (B22.249.R1). A secondary anti-mouse IgG
phycoerythrin antibody (Accurate Chemical, Westbury, NY) was
used was used at 10 mg/mL to detect H-2D
b expression. MHC I
transgenic constructs were injected into FVB/Cr blastocysts to
generate H-2K
b, H-2D
b and H-2K
ba1a2D
b transgenic mice.
Figure 5. Surface expression of H-2 transgenes is regulated by genomic elements outside of sequences encoding peptide binding
domains. (A) The mean fluorescence intensity (MFI) for peripheral blood lymphocytes stained with the H-2D
b specific antibody B22.249 from H-2
b
haplotype mice (white) and transgenic mice (gray); (* Line 1 v. B10 or FVB D
b,p ,0.05,
a Line 2 v. B10 or FVB D
b,p ,0.05). (B) Splenocytes from mice
infected with TMEV for 21 days were isolated and tested by flow cytometry for H-2D
b expression levels using B22.249.R1 labeled with FITC. Data are
expressed as the MFI of the FITC labeled cells (* p,0.05, Two-way ANOVA). (C) The same splenocytes in (B) were co-stained with AF6-88.5 labeled
phycoerythrin to determined expression of the H-2K
b present on the chimeric K
ba1a2D
b molecule. Data are expressed as MFI of PE labeled cells
(* p,0.001, Two-way ANOVA). (D) Brain resident cells from FVB, FVB D
b and FVB K
ba1a2D
b mice were isolated from naı ¨ve mice and analyzed by flow
cytometry. Side-scatter and forward-scatter were analyzed for the presence of mononuclear resident cells using a lymphocyte gate. Resident antigen-
presenting cells were further analyzed by a CD45 mid-level staining gate and assessed for expression of MHC class I. FVB (green), FVB D
b (black) and
FVB K
ba1a2D
b (blue) brain cells were assessed for H-2D
b expression by FACS (* p,0.001, t-test). (E) Brain cells isolated from 6 day TMEV infected mice
were gated as in (D) and assessed for changes in H-2D
b expression by FACS. Data are the MFI for H-2D
b-FITC.
doi:10.1371/journal.ppat.1002541.g005
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b LoxP mouse to achieve cell-
specific deletion of the H-2D
b class I molecule through
modification of our H-2D
b transgene [12]. Using conventional
molecular biology techniques, we inserted LoxP sites that flank the
transmembrane exon of the D
b class I gene (exon 5). This drives
D
b class I gene expression in the FVB/N strain (H-2
q). Transgenic
FVB/N-D
b LoxP mice elicited normal CNS infiltrating D
b:
VP2 121–130 epitope specific CD8 T cell responses during acute
TMEV infection (data not shown). To verify function of the LoxP
transgene, we bred the FVB/N-D
b LoxP mice to the FVB/N-Tg
(E2a-cre) C5379Lmgd/J mouse (Jackson: 003314). This line
carries a Cre transgene under the control of the adenovirus E2a
promoter that targets expression of Cre recombinase in a wide
variety of tissues. Thymocytes isolated from progeny FVB/N-D
b
LoxP mice that expressing the Cre transgene under the E2a
promoter had deactivation of D
b class I expression (data not
shown).
Histology
Chronically infected mice were perfused and fixed with
Trump’s fixative before dissociated spinal cord sections were fixed
with osmium tetroxide, dehydrated, embedded in glycol methac-
rylate and sectioned as described previously [36]. Spinal cord
sections were analyzed for the presence of demyelination
characterized by the presence of focal lesions composed of
infiltrating lymphocytes, myelin debris and de-nuded axons.
Semi-Quantitative RT-PCR for TMEV, cytokine and MHC
class I mRNA
The 7900HT Fast Real-Time PCR System (Applied Biosys-
tems, Carlsbad, CA, USA) was used to quantify viral RNA
infected brain and spinal cord homogenates from mice inoculated
with TMEV-wt or TMEV-L/OVA. RNA was isolated using
TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) and reverse
transcribed using the Superscript cDNA synthesis kit (Invitrogen).
Reaction was set up using the Fast SyBR Green Master Mix Kit
(Applied Biosystems). cDNA was amplified using primers specific
for mouse actin (F – 59CTGGCACCACACCTTCTACAAT-
GAGCTG and R– 59GCACAGCTTCTCTTTGATGTCACG-
CACGATTTC) and for viral protein 2 (VP2) of TMEV (F-
59TGGTCGACTCTGTGGTTACG and R-59 GCCGGTCT-
TGCAAAGATAGT). Cycling conditions were as follows: 50uC
for 2 minutes, 95uC for 10 minutes followed by 40 cycles of 95uC
at 15 seconds then 55uC for 1 minute. Amplification curves and
crossing point thresholds were based on SYBR Green incorpora-
tion. Samples were normalized to actin and data are reported as
fold increase over background or the appropriate control strain.
Primers specific for H-2D
b (59GAAACACAGAAAGCCAA-
GGGCCAA and 59AGTCCGACCCCAAGTCACAGCCAG),
H-2D
q (59GATCACGCAGATCGCCAAGGACAAT and 59CG-
TGCAACCCCACGTCACAGCCGTACATCC), H-2L
q (59GT-
CCCGCAGGCACTCACACGATCCAG and 59CCGTCGT-
ATGCGTACTGCTCGTACCC) and H-2K
q (59ACGACACT-
GAGTTGGTGCGCTTCGAC and 59ACTCTGCTCATTG-
TCCTTGGCGATCT) were used to evaluate H-2 expression in
fibroblast, spinal cord and brain by semi-quantitative real-time
RT-PCR. Samples were normalized to actin and fold change was
calculated relative to non-transgenic or to background amplifica-
tion of mice not having the amplified allele.
To determine the relative contribution of different H-2 alleles to
the overall expression of MHC class I in the CNS, we used a
competitive PCR technology to amplify multiple MHC class I
alleles and then verified their identity by sequencing. We used
flanking primers that were conserved across several alleles but
spanned areas of diversity that allowed us to discriminate
individual alleles. We added flanking BamHI sites to each primer
so that concatamers could be generated from amplified fragments
(Forward 59CATATAATAATGGATCCTACTACAACCAGA-
GC, Reverse 59GTATATTATCGGATCCGTACCCGCGGA-
GGAG). Concatamers were cloned and sequenced using standard
techniques.
Skin fibroblasts
Skin fibroblast lines were derived from ear punches obtained
from FVB, FVB D
b and FVB K
ba1a2D
b transgenic mice
according to previously described methods [37].
Analysis of mRNA stability
mRNA stability was assessed using previously described
techniques [38]. Skin fibroblasts derived from FVB and transgenic
FVB D
b and FVB K
ba1a2D
b mice were treated with 1 mg/mL of
recombinant mouse interferon gamma (R&D Systems, Minneap-
olis, MN) in triplicate. Twenty-four hours later cells were either left
untreated or treated with 2.5 mg/mL of actinomycin D (Sigma-
Aldrich, St. Louis, MO) for 1, 3 and 6 hours. After actinomycin D
exposure RNA was extracted using TRIzol reagent. Real-time
RT-PCR assessment of fold reduction in expression of H-2D
b and
TNFa (Forward primer 59GGATGAGAAGTTCCCAAATGG-
CCTC and Reverse primer 59 GCTCCTCCACTTGGTG-
GTTTGCTA) was performed using actin as a normalization
control. Data were expressed as the fold reduction in expression
from the untreated control sample.
Analysis of central nervous system derived lymphocytes
Brain and spinal cord infiltrating lymphocytes from TMEV
infected mice were recovered using previously described tech-
niques and were analyzed by flow cytometry [10,39]. Anti-CD45
(30-F11) and anti-CD8 (53-6.7) antibodies were obtained from
Ebiosciences (San Diego, CA, USA). FITC labeled anti H-2D
b
(B22-249R1; Accurate, Westbury, NY, USA) and PE-labeled anti
H-2K
b (AF6-88.5; BD Pharmingen, San Jose, CA, USA) were
used to assess MHC class I expression on PBMC, splenocytes and
brain infiltrating cells. All antibodies were used in excess at
concentration of 10 mg/mL. VP2121–130/H-2D
b tetramers were
kindly provided by the NIH Tetramer Core Facility at Emory
University (Atlanta, GA, USA) and were used at a concentration of
12 mg/mL. HPV16 E749–57/H-2D
b tetramers (Becton-Dickinson,
San Jose, CA) were used as a non-specific control according to the
manufacturers guidelines. Samples were analyzed on a BD LSR II
flow cytometer (BD Biosciences, San Jose, CA) and analyzed using
FloJo software (Ashland, OR). Single color stained splenocytes
were used as compensation controls. CD45-allophycocyanin
staining was used to discriminate brain derived microglia that
moderately autofluoresce in the FL1 channel from other brain
derived cells. Comparisons between the three transgenic strains
were performed on the same population of CD45 gated cells.
Cytotoxic lymphocyte killing of VP2121 peptide pulsed targets was
assessed by chromium release assay using EL4 cells pulsed with
1 mg/mL of peptide [10].
Statistics
Normally distributed data were analyzed by ANOVA or t-test.
Data failing the normality test were analyzed by ANOVA on ranks
or Rank-sum test. Pairwise comparisons for ANOVA were
performed using the Holm-Sidak method. Significance was
determined by p less than 0.05.
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